P449. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months | Zendy

AI Assistant Blog Pricing

P449. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.